Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1953 1
1954 2
1956 1
1958 1
1960 1
1970 3
1973 2
1978 1
1981 5
1982 1
1983 7
1984 3
1985 3
1986 4
1987 3
1988 7
1989 2
1990 7
1991 5
1992 10
1993 6
1994 11
1995 8
1996 9
1997 11
1998 3
1999 14
2000 9
2001 10
2002 14
2003 14
2004 13
2005 18
2006 11
2007 16
2008 17
2009 16
2010 17
2011 25
2012 21
2013 13
2014 10
2015 18
2016 20
2017 14
2018 6
2019 12
2020 8
2021 15
2022 9
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

431 results

Results by year

Filters applied: . Clear all
Page 1
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Hauser SL, et al. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002679 Free article. Clinical Trial.
Polymyositis and dermatomyositis.
Dalakas MC, Hohlfeld R. Dalakas MC, et al. Among authors: hohlfeld r. Lancet. 2003 Sep 20;362(9388):971-82. doi: 10.1016/S0140-6736(03)14368-1. Lancet. 2003. PMID: 14511932 Review.
The role of the gut microbiota in multiple sclerosis.
Correale J, Hohlfeld R, Baranzini SE. Correale J, et al. Among authors: hohlfeld r. Nat Rev Neurol. 2022 Sep;18(9):544-558. doi: 10.1038/s41582-022-00697-8. Epub 2022 Aug 5. Nat Rev Neurol. 2022. PMID: 35931825 Review.
Role of B Cells in Multiple Sclerosis and Related Disorders.
Comi G, Bar-Or A, Lassmann H, Uccelli A, Hartung HP, Montalban X, Sørensen PS, Hohlfeld R, Hauser SL; Expert Panel of the 27th Annual Meeting of the European Charcot Foundation. Comi G, et al. Among authors: hohlfeld r. Ann Neurol. 2021 Jan;89(1):13-23. doi: 10.1002/ana.25927. Epub 2020 Nov 4. Ann Neurol. 2021. PMID: 33091175 Free PMC article. Review.
Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis.
Schneider-Hohendorf T, Gerdes LA, Pignolet B, Gittelman R, Ostkamp P, Rubelt F, Raposo C, Tackenberg B, Riepenhausen M, Janoschka C, Wünsch C, Bucciarelli F, Flierl-Hecht A, Beltrán E, Kümpfel T, Anslinger K, Gross CC, Chapman H, Kaplan I, Brassat D, Wekerle H, Kerschensteiner M, Klotz L, Lünemann JD, Hohlfeld R, Liblau R, Wiendl H, Schwab N. Schneider-Hohendorf T, et al. Among authors: hohlfeld r. J Exp Med. 2022 Nov 7;219(11):e20220650. doi: 10.1084/jem.20220650. Epub 2022 Sep 1. J Exp Med. 2022. PMID: 36048016 Free PMC article.
Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.
Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, Melms A, Tackenberg B, Schalke B, Schneider-Gold C, Zimprich F, Meuth SG, Wiendl H. Melzer N, et al. Among authors: hohlfeld r. J Neurol. 2016 Aug;263(8):1473-94. doi: 10.1007/s00415-016-8045-z. Epub 2016 Feb 17. J Neurol. 2016. PMID: 26886206 Free PMC article. Review.
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group. Kappos L, et al. Among authors: hohlfeld r. N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089952 Free article. Clinical Trial.
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
Kappos L, Fox RJ, Burcklen M, Freedman MS, Havrdová EK, Hennessy B, Hohlfeld R, Lublin F, Montalban X, Pozzilli C, Scherz T, D'Ambrosio D, Linscheid P, Vaclavkova A, Pirozek-Lawniczek M, Kracker H, Sprenger T. Kappos L, et al. Among authors: hohlfeld r. JAMA Neurol. 2021 May 1;78(5):558-567. doi: 10.1001/jamaneurol.2021.0405. JAMA Neurol. 2021. PMID: 33779698 Free PMC article. Clinical Trial.
431 results